Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Issue 11 (2nd November 2021)

• Record Type: Journal Article
• Authors: Crouse, Bethany; Zhang, Li; Robinson, Christine; Ban, Yuguang; Vigliaturo, Jennifer R; Roy, Sabita; Pravetoni, Marco
• Is Part Of: Human vaccines & immunotherapeutics. Volume 17:Issue 11(2021)
• Page Start: 4383
• Page End: 4392
• Publication Date: 2021-11-02
• Subjects: Opioids -- vaccine -- microbiome -- environment -- housing -- therapy; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.1954442
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Vaccines offer a promising prophylactic and therapeutic intervention to counteract opioid use disorders (OUD) and fatal overdoses. Vaccines generate opioid-specific antibodies that bind the target opioid, reducing drug distribution to the brain and preventing drug-induced behavioral and pharmacological effects. Due to their selectivity, anti-opioid vaccines can be administered in combination with FDA-approved medications. Because patients with OUD or other substance use disorders may be affected by other multifactorial co-morbidities, such as infection or depression, it is important to test whether vaccine efficacy is modified by factors that may impact individual innate or adaptive immunity. To that end, this study tested whether housing conditions would affect the efficacy of two lead vaccine formulations targeting oxycodone and fentanyl in male mice and rats, and further analyzed whether differences in the gastrointestinal (GI) microbiome would be correlated with either vaccine efficacy or housing conditions. Results showed that housing mice and rats in either conventional (non-controlled) or specific pathogen-free (SPF, sterile barrier maintained) environment did not affect vaccine-induced antibody responses against oxycodone and fentanyl, nor their efficacy against oxycodone- and fentanyl-induced antinociception, respiratory depression, and bradycardia. Differences in the GI microbiome detected via 16S rRNA gene sequencing were related to the housing environment. This study supports use of anti-opioid vaccines in clinical populations that may display deficits in microbiome function.